Antimicrobial therapy of severe “civilian” intra-abdominal infections: a modern approach to empiric antibiotic therapy

O Domoratsky; D Yaroshuk; V Gladkih; D Mykhaylenko; O Pavlenko

doi:10.31636/prmd.v6i1.1

Автор(и)

O Domoratsky P. L. Shupyk National Public Health University, “MEDICOM Clinic” PE
D Yaroshuk The Department of Surgery of the Faculty of Stomatology of the NSU named after O. O. Bogomolets
V Gladkih KNP “Vinnytsia Regional Clinical Treatment and Diagnostic Center of Cardiovascular Pathology”
D Mykhaylenko PE “Clinic MEDICOM”
O Pavlenko KNP “Kyiv City Clinical Emergency Medical Hospital”

DOI:

https://doi.org/10.31636/prmd.v6i1.1

Ключові слова:

інтраабдомінальні інфекції, інтенсивна терапія, емпірична антибіотикотерапія, піперацилін/тазобактам

Анотація

У цій публікації обговорюються проблеми лікування важких інтраабдомінальних інфекцій, а саме: емпірична антимікробна терапія вторинних перитонітів з огляду на сучасний стан питання в розумінні авторів, сучасних настанов та наказів МОЗ України. Місця використання добре відомого, але нового для України препарату піперацилін / тазобактаму, карбапенемів, антибіотиків резерву. Ми не розглядаємо тут кандидозний, первинний і третинний перитоніти; сподіваємось приділити цьому увагу в наступних публікаціях.

Завантажити

Дані для завантаження поки недоступні.

Посилання

Vincent JL, Sakr Y, Singer M, MartinLoeches I, Machado FR, Marshall JC, et al. Prevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017. JAMA [Internet]. 2020 Apr 21;323(15):1478–87. Available from: https://doi.org/10.1001/jama.2020.2717

Volakli E, Spies C, Michalopoulos A, Groeneveld AJ, Sakr Y, Vincent JL. Infections of respiratory or abdominal origin in ICU patients: what are the differences? Critical Care [Internet]. 2010;14(2):R32. Available from: https://doi.org/10.1186/cc8909

Righolt CH, LagaceWiens P, Mahmud SM. Prevalence, predictors, and consequences of inappropriate empiric antimicrobial therapy for complicated urinary tract and intraabdominal infections in Winnipeg hospitals. Diagnostic Microbiology and Infectious Disease [Internet]. 2020 Jan;96(1):114891. Available from: https://doi.org/10.1016/j.diagmicrobio.2019.114891

Zhang J, Yu WQ, Chen W, Wei T, Wang CW, Zhang JY, et al. Systematic Review and MetaAnalysis of the Efficacy of Appropriate Empiric AntiEnterococcal Therapy for IntraAbdominal Infection. Surgical Infections [Internet]. 2021 Mar 1;22(2):131–43. Available from: https://doi.org/10.1089/sur.2020.001

Vogelaers D, Blot S, Van den Berge A, Montravers P, Francois G, Labeau S, et al. Antimicrobial Lessons From a Large Observational Cohort on Intraabdominal Infections in Intensive Care Units. Drugs [Internet]. 2021 May 26;81(9):1065–78. Available from: https://doi.org/10.1007/s4026502101534w

Blot S, Antonelli M, Arvaniti K, Blot K, CreaghBrown B, et al. Epidemiology of intraabdominal infection and sepsis in critically ill patients: “AbSeS”, a multinational observational cohort study and ESICM Trials Group Project. Intensive Care Medicine [Internet]. 2019 Oct 29;45(12):1703–17. https://doi.org/10.1007/s00134019058193

Surveillance atlas of infectious diseases [Internet]. European Centre for Disease Prevention and Control; [cited 2023 Sep 27]. Available from: https://atlas.ecdc.europa.eu/public/

Rhee C, Jones TM, Hamad Y, Pande A, Varon J, O’Brien C, et al. Prevalence, Underlying Causes, and Preventability of SepsisAssociated Mortality in US Acute Care Hospitals. JAMA Network Open [Internet]. 2019 Feb 15;2(2):e187571. Available from: https://doi.org/10.1001/jamanetworkopen.2018.7571

Reitz KM, Kennedy J, Li SR, Handzel R, Tonetti DA, Neal MD, et al. Association Between Time to Source Control in Sepsis and 90Day Mortality. JAMA Surgery [Internet]. 2022 Sep 1;157(9):817–26. Available from: https://doi.org/10.1001/jamasurg.2022.2761

Coccolini F, Sartelli M, Sawyer R, Rasa K, Viaggi B, AbuZidan F, et al. Source control in emergency general surgery: WSES, GAIS, SISE, SISA guidelines. World Journal of Emergency Surgery [Internet]. 2023 Jul 21;18(1). Available from: https://doi.org/10.1186/s13017023005094

Mazuski JE, Tessier JM, May AK, Sawyer RG, Nadler EP, Rosengart MR, et al. The Surgical Infection Society Revised Guidelines on the Management of IntraAbdominal Infection. Surgical Infections [Internet]. 2017 Jan;18(1):1–76. Available from: https://doi.org/10.1089/sur.2016.261

Murao N, Ohge H, Ikawa K, Watadani Y, Uegami S, Shigemoto N, et al. Pharmacokinetics of piperacillintazobactam in plasma, peritoneal fluid and peritoneum of surgery patients, and dosing considerations based on sitespecific pharmaco-dynamic target attainment. International Journal of Anti-microbial Agents [Internet]. 2017 Sep;50(3):393–8. Available from: https://doi.org/10.1016/j.ijantimicag.2017.03.025

Buckley MS, Komerdelj IA, D’Alessio PA, Rangan P, Agarwal SK, Tinta NC, et al. Vancomycin with concomitant piperacillin/tazobactam vs. cefepime or meropenem associated acute kidney injury in the critically ill: A multicenter propensity scorematched study. Journal of Critical Care [Internet]. 2022 Feb;67:134–40. Available from: https://doi.org/10.1016/j.jcrc.2021.10.018

Spicer WJ. Clinical Microbiology And Infectious Diseases: An Illustrated Colour Text. 2th ed. : Published by Churchill Livingstone; 2007. 264 p.

Patrick S. Bacteroides. Chapter 51 In: YiWei Tang, Max Sussman, Dongyou Liu, Ian Poxton, Joseph Schwartzman, eds. Molecular Medical Microbiology. 2th ed. [Internet]. Academic Press; 2015. p. 917–44. Available from: https://doi.org/10.1016/b9780123971692.000512

Nagy E, Urbán E, Nord CE. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe: 20 years of experience. Clinical Microbiology and Infection [Internet]. 2011 Mar;17(3):371–9. Available from: https://doi.org/10.1111/j.14690691.2010.03256.x

Li C, Kuti JL, Nightingale CH, Mansfield DL, Dana A, Nicolau DP. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intraabdominal infection. Journal of Antimicrobial Chemotherapy [Internet]. 2005 Jul 7;56(2):388–95. Available from: https://doi.org/10.1093/jac/dki243

Karaiskos I, Lagou S, Pontikis K, Rapti V, Poulakou G. The “Old” and the “New” Antibiotics for MDR GramNegative Pathogens: For Whom, When, and How. Frontiers in Public Health [Internet]. 2019 Jun 11;7. Available from: https://doi.org/10.3389/fpubh.2019.00151

De Oliveira DMP, Forde BM, Kidd TJ, Harris PNA, Schembri MA, Beatson SA, et al. Antimicrobial Resistance in ESKAPE Pathogens. Clinical Microbiology Reviews [Internet]. 2020 Jun 17;33(3) :e0018119. Available from: https://doi.org/10.1128/cmr.0018119

Hawkey PM, Warren RE, Livermore DM, McNulty CAM, Enoch DA, Otter JA, et al. Treatment of infections caused by multidrugresistant Gramnegative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party†. Journal of Antimicrobial Chemotherapy [Internet]. 2018 Mar 1;73(suppl_3):iii2–78. Available from: https://doi.org/10.1093/jac/dky027

Paul M, Carrara E, Retamar P, Tängdén T, Bitterman R, Bonomo RA, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrugresistant Gramnegative bacilli (endorsed by European society of intensive care medicine). Clinical Microbiology and Infection [Internet]. 2022 Apr;28(4):521–47. Available from: https://doi.org/10.1016/j.

cmi. 2021.11.025

Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America 2022 Guidance on the Treatment of ExtendedSpectrum βlactamase Producing Enterobacterales (ESBLE), CarbapenemResistant Enterobacterales (CRE), and Pseudomonas aeruginosa with DifficulttoTreat Resistance (DTRP. aeruginosa). Clinical Infectious Diseases [Internet]. 2022 Apr 19;75(2):187–212. Available from: https://doi.org/10.1093/cid/ciac268

Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America Guidance on the Treatment of AmpC βLactamase–Producing Entero- bacterales, CarbapenemResistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections. Clinical Infectious Diseases [Internet]. 2021 Dec 5;74(12):2089–114. Available from: https://doi.org/10.1093/cid/ciab1013

Bassetti M, Garau J. Current and future perspectives in the treatment of multidrugresistant Gramnegative infections. Journal of Antimicrobial Chemotherapy [Internet]. 2021 Nov 1;76(Supplement_4):iv23–37. Available from: https://doi.org/10.1093/jac/dkab352

Marothi YA, Agnihotri H, Dubey D. Enterococcal resistancean overview. Indian J Med Microbiol [Internet]. 2005 Oct;23(4):214–9. PMID: 16327115. Available from: https://pubmed.ncbi.nlm.nih.gov/16327115/

Buckley MS, Komerdelj IA, D’Alessio PA, Rangan P, Agarwal SK, Tinta NC, et al. Vancomycin with concomitant piperacillin/tazobactam vs. cefepime or meropenem associated acute kidney injury in the critically ill: A multicenter propensity scorematched study. Journal of Critical Care [Internet]. 2022 Feb;67:134–40. Available from: https://doi.org/10.1016/j.jcrc.2021.10.018

Guilbart M, Zogheib E, Ntouba A, Rebibo L, Régimbeau JM, Mahjoub Y, et al. Compliance with an empirical antimicrobial protocol improves the outcome of complicated intraabdominal infections: a prospective observational study. British Journal of Anaesthesia [Internet]. 2016 Jul;117(1):66–72. Available from: https://doi.org/10.1093/bja/aew117